NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ORTINGLOBE · data 2026-10-30
Ortin Global Ltd
In plain words
Price: 37.3% below its 52-week high of ₹21.3.
Delivery: 77.5% of traded shares were kept for delivery over the last 10 sessions, against 79.1% over the last 60.
Latest results: a net loss of ₹0 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹0 cr |
| Net profit (last 12 months) | ₹-1 cr |
| Sales growth, 3 years (yearly) | -74.4% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 1.2% (unchanged in a year), pledged 0.0%, institutions 0.7%.
ROE -46.1%, ROCE -46.3%, operating margin -1521.1%: how much profit it earns on the money it uses.
Debt/equity 0.81, Profit growth — and sales growth -74.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-46.1%).
- Thin operating margin (-1521.1%).
- Reported a loss in the latest quarter.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
ORTINGLOBE Q1 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹0.01 crore, down 75% YoY and down 66.7% QoQ.
Net loss was ₹0.34 crore, a bigger loss than a year ago and a bigger loss than last quarter.
Operating margin was 2,919.8% (511.6% a year ago).
EPS was -₹0.42, more negative than a year ago and more negative than last quarter.
ORTINGLOBE के Q1 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹0.01 करोड़; पिछले साल की तुलना में 75% की गिरावट, पिछली तिमाही की तुलना में 66.7% की गिरावट।
शुद्ध घाटा: ₹0.34 करोड़; एक साल पहले से घाटा बढ़ा, पिछली तिमाही से घाटा बढ़ा।
ऑपरेटिंग मार्जिन: 2,919.8% (एक साल पहले 511.6%)।
EPS: -₹0.42; एक साल पहले से अधिक ऋणात्मक, पिछली तिमाही से अधिक ऋणात्मक।
ORTINGLOBEના Q1 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹0.01 કરોડ; ગયા વર્ષની સરખામણીએ 75% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 66.7% ઘટાડો.
ચોખ્ખી ખોટ: ₹0.34 કરોડ; એક વર્ષ પહેલાંની સરખામણીએ ખોટ વધી, ગયા ક્વાર્ટરની સરખામણીએ ખોટ વધી.
ઓપરેટિંગ માર્જિન: 2,919.8% (એક વર્ષ પહેલાં 511.6%).
EPS: -₹0.42; એક વર્ષ પહેલાંના કરતાં વધુ નકારાત્મક, ગયા ક્વાર્ટરના કરતાં વધુ નકારાત્મક.
Written from the filed numbers. Not a recommendation.
Smart-money activity
12/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 77.0% over the last 20 sessions vs 79.3% in the 40 before (0.97x); shares delivered per day 0.54x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 7/20: Net +₹0.07 cr bought in bulk/block deals over 90 days; 1 net buying day, 0 net selling days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Results
- 8 Sept 26Deal Bulk deal: SRINIVASARAO KARI bought ₹0.07 cr +0.6% next session
- 14 Aug 26Results Q1 FY27 results: loss widened vs a year ago -0.7% next session
- 30 May 26Results Q4 FY26 results: loss narrowed vs a year ago -3.2% next session
- 14 Feb 26Results Q3 FY26 results: loss narrowed vs a year ago +5.0% next session
- 14 Nov 25Results Q2 FY26 results: loss widened vs a year ago -6.3% next session
- 14 Aug 25Results Q1 FY26 results: loss widened vs a year ago -9.8% next session
- 26 May 25Results Q4 FY25 results: loss narrowed vs a year ago -1.5% next session
- 12 Feb 25Results Q3 FY25 results: loss narrowed vs a year ago -3.4% next session
- 14 Nov 24Results Q2 FY25 results: loss narrowed vs a year ago -2.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹0 cr | ₹-0 cr | — | -2919.8% | -0.42 |
| Mar 2026 | ₹0 cr | ₹-0 cr | — | -816.3% | -0.01 |
| Dec 2025 | ₹0 cr | ₹-0 cr | — | -401.6% | -0.07 |
| Sept 2025 | ₹0 cr | ₹-1 cr | — | -3581.4% | -0.62 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 1.24% | 1.23% | 1.23% | 1.23% |
| Foreign institutions (FII) | 0.67% | 1.80% | 1.68% | 1.68% |
| Domestic institutions (DII) | — | — | — | — |
| Mutual funds | — | — | — | — |
| Retail investors | 55.03% | 54.45% | 54.19% | 58.38% |
| Number of shareholders | 11,151 | 11,383 | 11,452 | 11,834 |
Common questions
What was Ortin Global Ltd's latest quarterly profit?
Ortin Global Ltd reported a net loss of ₹0 cr for the quarter ended Jun 2026, on revenue of ₹0 cr.
How much do promoters hold in Ortin Global Ltd?
Promoters held 1.24% of Ortin Global Ltd at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Ortin Global Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.81.
What is the 52-week high and low of Ortin Global Ltd?
The 52-week high is ₹21.3 and the 52-week low is ₹10.83.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Ortin Global Ltd | ₹13.35 | ₹10 cr | — | — | -46.1% | -46.3% | 0.81 | +18.7% |
| Biofil Chemicals & Pharmaceuticals Ltd. | ₹28.68 | ₹47 cr | 96.4 | — | 13.8% | 1.8% | 0.14 | -27.5% |
| Medicamen Organics Ltd. | ₹26.5 | ₹39 cr | — | — | -13.7% | -15% | 0.5 | -24.6% |
| Medi-Caps Ltd. | ₹24.69 | ₹30 cr | — | — | -2.6% | -9.5% | 0 | -5.8% |
| Lasa Supergenerics Ltd. | ₹4.67 | ₹25 cr | — | — | -51.1% | -27% | 0.2 | -55.1% |
| Sunrest Lifescience Limited | ₹39.25 | ₹17 cr | 4.5 | 0.8 | 22.4% | 25.9% | 0.85 | -6.5% |
Compare ORTINGLOBE with BIOFILCHEM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ORTINGLOBE in NSE Scanner →